BR0113980A - Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear - Google Patents
Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclearInfo
- Publication number
- BR0113980A BR0113980A BR0113980-0A BR0113980A BR0113980A BR 0113980 A BR0113980 A BR 0113980A BR 0113980 A BR0113980 A BR 0113980A BR 0113980 A BR0113980 A BR 0113980A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- modulators
- hormone receptor
- analogs
- fused heterocyclic
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title abstract 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 2
- -1 heterocyclic succinimide compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001923 cyclic compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23351900P | 2000-09-19 | 2000-09-19 | |
| US28443801P | 2001-04-18 | 2001-04-18 | |
| US28473001P | 2001-04-18 | 2001-04-18 | |
| PCT/US2001/019655 WO2002024702A1 (en) | 2000-09-19 | 2001-06-20 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0113980A true BR0113980A (pt) | 2003-06-24 |
Family
ID=27398441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0113980-0A BR0113980A (pt) | 2000-09-19 | 2001-06-20 | Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear |
Country Status (36)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001911B2 (en) | 2000-06-28 | 2006-02-21 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
| US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2001288213B2 (en) * | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
| EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US6953679B2 (en) | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| AU2002364082A1 (en) | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| EP1553074B1 (en) | 2002-08-12 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| WO2004110978A2 (en) * | 2003-06-10 | 2004-12-23 | Smithkline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
| US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| WO2007015567A1 (ja) * | 2005-08-01 | 2007-02-08 | Takeda Pharmaceutical Company Limited | 環状アミン化合物 |
| US20100004249A1 (en) * | 2006-07-11 | 2010-01-07 | Takahiro Matsumoto | Bicyclic heterocyclic compound and use thereof |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| EP2455370A1 (en) | 2009-07-17 | 2012-05-23 | Shionogi&Co., Ltd. | Pharmaceutical product containing lactam or benzene sulfonamide compound |
| PL2782584T3 (pl) | 2011-11-23 | 2021-12-13 | Therapeuticsmd, Inc. | Naturalne skojarzone hormonalne formulacje i terapie zastępcze |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN112584832A (zh) | 2018-06-14 | 2021-03-30 | 斯克里普斯研究学院 | 用于物质使用复发的非肌肉肌球蛋白ii抑制剂 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| WO2022061226A1 (en) * | 2020-09-19 | 2022-03-24 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting trem-1 |
| CN115340483A (zh) * | 2022-08-31 | 2022-11-15 | 南京吉星生物技术开发有限公司 | 一种萘基吡咯啉二酮化合物及其制备方法与它的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
| JPS5046697A (cg-RX-API-DMAC7.html) * | 1973-08-20 | 1975-04-25 | ||
| US5539126A (en) * | 1994-04-20 | 1996-07-23 | Bristol-Myers Squibb Company | Method for preparing homochiral maleimide intermediates, via silylation techniques |
| DK0800519T3 (da) * | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroidreceptormodulatorforbindelser og fremgangsmåder |
| WO1997049709A1 (en) * | 1996-06-27 | 1997-12-31 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP0979407A1 (en) * | 1997-04-29 | 2000-02-16 | The Salk Institute For Biological Studies | Methods for identifying ligands for nuclear hormone receptors |
| US7101681B1 (en) * | 1997-11-21 | 2006-09-05 | Amgen, Inc. | Nuclear hormone receptor drug screens |
| EP1214325B1 (en) * | 1999-09-10 | 2005-11-09 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| AU2001288213B2 (en) * | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
-
2001
- 2001-06-20 HK HK03106433.9A patent/HK1054230B/en not_active IP Right Cessation
- 2001-06-20 HR HR20030305A patent/HRP20030305B9/xx not_active IP Right Cessation
- 2001-06-20 EE EEP200300108A patent/EE200300108A/xx unknown
- 2001-06-20 JP JP2002529112A patent/JP4966477B2/ja not_active Expired - Fee Related
- 2001-06-20 KR KR1020037004018A patent/KR100765670B1/ko not_active Expired - Fee Related
- 2001-06-20 CN CNA200710006341XA patent/CN1995039A/zh active Pending
- 2001-06-20 BR BR0113980-0A patent/BR0113980A/pt not_active IP Right Cessation
- 2001-06-20 IL IL15501901A patent/IL155019A0/xx unknown
- 2001-06-20 ES ES01948503T patent/ES2260244T3/es not_active Expired - Lifetime
- 2001-06-20 CZ CZ2003780A patent/CZ2003780A3/cs unknown
- 2001-06-20 YU YU20003A patent/YU20003A/sh unknown
- 2001-06-20 GE GE5206A patent/GEP20074144B/en unknown
- 2001-06-20 MX MXPA03002412A patent/MXPA03002412A/es active IP Right Grant
- 2001-06-20 PL PL36170701A patent/PL361707A1/xx unknown
- 2001-06-20 NZ NZ524803A patent/NZ524803A/en unknown
- 2001-06-20 PT PT01948503T patent/PT1319007E/pt unknown
- 2001-06-20 CA CA002423071A patent/CA2423071A1/en not_active Abandoned
- 2001-06-20 AU AU6994301A patent/AU6994301A/xx active Pending
- 2001-06-20 SK SK498-2003A patent/SK4982003A3/sk unknown
- 2001-06-20 HU HU0400455A patent/HUP0400455A3/hu unknown
- 2001-06-20 DK DK01948503T patent/DK1319007T3/da active
- 2001-06-20 UA UA2003043564A patent/UA78686C2/uk unknown
- 2001-06-20 EP EP01948503A patent/EP1319007B9/en not_active Expired - Lifetime
- 2001-06-20 WO PCT/US2001/019655 patent/WO2002024702A1/en not_active Ceased
- 2001-06-20 US US09/885,381 patent/US20040176324A1/en not_active Abandoned
- 2001-06-20 CN CNB018189350A patent/CN1307181C/zh not_active Expired - Fee Related
- 2001-06-20 DE DE60117551T patent/DE60117551T2/de not_active Expired - Lifetime
- 2001-06-20 AU AU2001269943A patent/AU2001269943B2/en not_active Ceased
- 2001-06-20 AT AT01948503T patent/ATE318822T1/de active
- 2001-06-27 TW TW090115632A patent/TWI305208B/zh not_active IP Right Cessation
- 2001-06-28 AR ARP010103101A patent/AR035340A1/es unknown
- 2001-06-28 UY UY26808A patent/UY26808A1/es not_active Application Discontinuation
- 2001-06-28 MY MYPI20013097A patent/MY138531A/en unknown
- 2001-08-22 PE PE2001000656A patent/PE20020729A1/es not_active Application Discontinuation
-
2003
- 2003-03-18 IS IS6750A patent/IS6750A/is unknown
- 2003-03-19 NO NO20031266A patent/NO329931B1/no not_active IP Right Cessation
- 2003-03-26 BG BG107675A patent/BG107675A/bg unknown
- 2003-04-15 ZA ZA200302963A patent/ZA200302963B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0113980A (pt) | Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear | |
| BR0215281A (pt) | Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores da função do receptor de hormÈnio nuclear | |
| BR0111869A (pt) | Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear | |
| AU2002364082A8 (en) | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function | |
| BRPI9917007B8 (pt) | azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso | |
| MY116002A (en) | Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis | |
| ATE420880T1 (de) | Kondensierte zyklische modulatoren der funktion von nuklearen hormonrezeptoren | |
| BR9916585A (pt) | Moduladores de ccr5 | |
| BR9901491A (pt) | 7-hetero-biciclo [2.2.1] - heptanos. | |
| DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
| CL2009001278A1 (es) | Compuestos biciclicos, derivados de 1-(4-pipridinil)-1,3-dihidro-2h-indol-2-ona sustituidos, analogos de nociceptina; composicion farmaceutica; y su uso en el tratamiento del dolor (div. sol. 2103-03) | |
| UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
| MX9300407A (es) | Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion. | |
| BR9909486A (pt) | Compostos calcilìticos | |
| DK0644878T3 (da) | 2,5-Dioxo-2,5-dihydro-1H-benz[b[azepiner som NDMA-receptor-antagonister | |
| MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| EA200000198A1 (ru) | 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов | |
| TR199901385T2 (xx) | Piperidin t�revleri. | |
| PL366565A1 (en) | Fused cyclic modulators of nuclear hormone receptor function | |
| YU26001A (sh) | Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora | |
| MY131858A (en) | Active ingredient combination for the pharmacological therapy of nicotine dependence | |
| BR0107179A (pt) | Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona | |
| TR200000916T2 (tr) | İkameli piperidin türevleri. | |
| MX9301870A (es) | Antagonistas receptores de angiotensina ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUI DADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |